MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.5% – Time to Buy?

MoonLake Immunotherapeutics (NASDAQ:MLTX) shares rose 8.5% during mid-day trading on Tuesday . The stock traded as high as $16.97 and last traded at $17.1030. Approximately 637,267 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 2,723,124 shares. The stock had previously closed at $15.77.

Wall Street Analyst Weigh In

MLTX has been the topic of a number of analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, November 6th. BTIG Research restated a “buy” rating and issued a $24.00 price target on shares of MoonLake Immunotherapeutics in a research note on Monday, February 9th. Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, February 3rd. Finally, UBS Group set a $24.00 target price on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $25.77.

MoonLake Immunotherapeutics Stock Up 11.1%

The firm has a market cap of $1.13 billion, a PE ratio of -5.28 and a beta of 1.21. The firm’s 50 day moving average is $14.94 and its 200-day moving average is $25.07. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 70,000 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00. Following the completion of the sale, the chief executive officer owned 2,878,577 shares of the company’s stock, valued at $41,710,580.73. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 402,908 shares of company stock valued at $5,987,162. 12.02% of the stock is owned by company insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Decheng Capital LLC bought a new stake in shares of MoonLake Immunotherapeutics during the 2nd quarter worth $8,572,000. Jennison Associates LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the second quarter valued at $2,941,000. Schroder Investment Management Group acquired a new position in shares of MoonLake Immunotherapeutics in the 2nd quarter valued at $915,000. Elevation Point Wealth Partners LLC purchased a new position in MoonLake Immunotherapeutics in the 2nd quarter worth about $74,000. Finally, Boxer Capital Management LLC acquired a new stake in MoonLake Immunotherapeutics during the 3rd quarter worth about $1,792,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.